Clinuvel Pharmaceuticals (CLVLY) Stock Price, News & Analysis

Company Overview

Clinuvel Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on developing treatments for patients with severe and rare skin disorders. Its research centers on melanocortin analogues, which are designed to stimulate the body’s natural melanin production and provide photoprotection without exposure to ultraviolet radiation.

The company’s lead product is SCENESSE, an afamelanotide implant approved in the United States, European Union and Australia for the prevention of phototoxic reactions in adults with erythropoietic protoporphyria, a rare genetic disorder that can cause intense pain and skin damage following exposure to light. Clinuvel also evaluates afamelanotide and related compounds for additional dermatological and photoprotective applications.

Clinuvel is headquartered in Melbourne, Australia, and serves patients and healthcare markets across Australia, Europe and North America. The company was established in the 1980s and has operated under the Clinuvel name since the 2000s. Its executive leadership has included Chief Executive Officer Philippe Wolgen, who has led the company’s development and commercialization activities.

Key Stats

• Today's Range: $7.28 to $7.52
• 50-Day Range: $7.35 to $7.35
• 52-Week Range: $5.98 to $9.00
• Volume: 36,763 shs
• Average Volume: 3,028 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Consumer Discretionary
• Industry: Diversified Consumer Services
• Sub-Industry: Specialized Consumer Services
• Current Symbol: OTCMKTS:CLVLY
• CIK: 1290877
• Web: www.clinuvel.com
• Phone: (139) 660-4900
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A